Sentynl Therapeutics, Inc, a US-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), has announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of Nulibry (fosdenopterin) for injection as the first therapy for the treatment of patients in Great Britain with molybdenum cofactor deficiency (MoCD) type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants. MoCD type A is known to impact fewer than 150 patients globally with a median survival age of four years.
SOLANA BEACH, Calif., April 16, 2024 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients in Great Britain (GB) with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants. MoCD Type A is known to impact fewer than 150 patients globally with a median survival age of four years.
SOLANA BEACH, Calif., Sept. 7, 2023 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem. NULIBRY is indicated to reduce the risk of mortality in patients with MoCD Type A, an ultra-rare, autosomal recessive, inborn error of metabolism causing sulfite-induced neurodegeneration and early death.
Comharsa`s Nulibry (Fosdenopterin) Receives Approval in Europe
PALO ALTO, Calif. and SOLANA BEACH, Calif. and AHMEDABAD, India, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the European Commission (EC) has granted marketing authorization for NULIBRY® (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is an ultra-rare and progressive condition known to impact less than 150 patients globally with a median survival of four years.
BridgeBio, Sentynl and Medison Pharma Announce Approval in Israel for NULIBRY
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and...
Sentynl Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus Lifesciences Ltd focused on bringing innovative therapies to patients living with rare diseases and BridgeBio Pharma, Inc., announced the execution of an asset purchase agreement (the Agreement) for the sale of BridgeBio’s Nulibry (Fosdenopterin) for injection.
Now part of the fold at AstraZeneca, rare disease specialist Alexion doesn’t miss often when it comes to taking meds across the finish line. But in one special case, BridgeBio took an Alexion castoff on board — and now it’s turned the drug into a winner.
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.